NextPoint is a company focused on precision immuno-oncology and tumor-targeting therapeutics. They work on the B7-H7/HHLA2 axis, integrating foundational science with a defined clinical biomarker to identify patient populations for B7-H7-directed therapy.

NextPoint

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.

Sixty Degree Capital

Sanofi Ventures

PagodaTree Partners

Leaps by Bayer

MPM Capital

Invus

Binney Street Capital

Catalio Capital Management

Gordon Freeman

NextPoint Therapeutics, Inc.

#ICYMI, be sure to check out the poster @NextPoint presented at CIMT in May: “Targeting B7-H7-mediated immunosuppression with NPX267 and NPX887, two fully humanized monoclonal antibodies that target KIR3DL3 and B7-H7, respectively”

For more information on how NextPoint’s new class of therapeutics may improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com.

We are thrilled to announce that our CEO, Ivan Cheung, will be speaking at the Longwood Healthcare Leaders Spring MIT event! Join us for two days of discussion and networking with biopharmaceutical leaders. Co-hosted by Koch Institute Professors Phil Sharp and Bob Langer and held at MIT’s Koch Institute, June 17-18, 2024. 

https://lnkd.in/exxKDits

Longwood Healthcare Leaders Longwood Fund #longwoodhealthcareleaders

Chief Medical Officer Leena Gandhi spoke last week at the Next-Gen Immuno-Oncology Conference in Boston about NextPoint Therapeutics, Inc.'s novel class of therapeutics targeting the B7-H7 pathway to improve treatment options for cancer therapy.

For more information on NextPoint’s new class of therapeutics to improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com.

Congratulations to NextPoint co-founder Dr. Gordon Freeman!

A nice behind the scenes look at how NextPoint scientific co-founder XingXing Zang's research translated to NPX267, our first clinical immuno-oncology program, currently in Phase 1a/1b clinical trials.

As we continue to push the boundaries of possibility, we are immensely grateful to be part of the LabCentral community.  LabCentral is the heart of our innovation and we're excited to share the impressive success of LabCentral and their 2023 Impact Report.

https://lnkd.in/eAxUk4T3

LabCentral has state-of-the-art facilities with access to top-tier resources where brilliant minds come together and make magic every day.  #Innovation #Collaboration #LabCentral #Science #Technology #Research

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Aug 5, 2024 2:47 PM	4d308d38
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 30, 2024 12:11 AM	d0a3e6d4
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
peers	general	Aug 5, 2024 2:47 PM	4ce287f0
news basic	general	Aug 5, 2024 2:47 PM	4c4b378b
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
logo	meta
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:NEXTPOINTTX

NextPoint